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ABSTRACT
Introduction:Muscle wasting conditions such as sarcopenia may be highly prevalent
in advanced head and neck cancer (HNC) patients (16–71%), with these prevalence
rates substantially greater in those who have received chemo-radiotherapy (CRT).
According to the updated European Working Group on Sarcopenia in Older People
consensus statement, sarcopenia is deﬁned as the age-related loss of muscle strength,
muscle mass and physical performance. The high prevalence of sarcopenia in HNC
patients is concerning as it has been associated with substantially increased risk of
CRT toxicity, respiratory complications and early mortality. With the high
prevalence of HNC and sarcopenia in India and the strong link between sarcopenia
and poor HNC patient outcomes, it is important to screen for the presence of
sarcopenia in Indian patients receiving CRT for HNC.
Methods: This longitudinal pilot study aimed to routinely monitor 19 men receiving
CRT for their HNC for a variety of sarcopenic-related outcomes over three time
points during their 7 weeks of CRT. Participants were required to be male, with a
minimum age of 30 years, with a Stage III, IVa or IVb diagnosis of HNC and be
currently undergoing a 7 weeks course of CRT in an oncology department. Outcomes
included probable sarcopenic diagnosis were estimated by the SARC-F, handgrip
strength, skeletal muscle mass was estimated by bioelectrical impedance and physical
performance was assessed by the Timed Up and Go. Repeated measures ANOVA
and Bonferroni post-hoc tests were used to identify signiﬁcant differences at the three
time points with a p < 0.05.
Results: The 19 participants in this trial at a mean age of 56.5 ± 10.2 years
(range = 39–75 years), with most (n = 13, 68.4%) employed in laboring occupations.
At baseline, 31.5% (n = 6) of the participants already had probable sarcopenia based
on their total SARC-F score, with this increasing to 89.4% (n = 17) at the end of
7 weeks CRT. In addition, signiﬁcant decreases in strength, skeletal muscle mass and
Timed Up and Go performance were observed, with these declines signiﬁcantly
greater at 7 weeks than 3 weeks after commencing CRT.
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Conclusions: Patients with HNC undergoing 7 weeks of CRT showed clinically
signiﬁcant increases in the incidence of probable sarcopenia based on their total
SARC-F score as well as clinically signiﬁcant declines in handgrip strength, skeletal
muscle mass and Timed Up and Go performance. Due to the relationship between
sarcopenia and a host of adverse events related to CRT in HNC patients, these results
suggest that oncologists and their allied health teams should routinely monitor these
patients during CRT and provide the relevant exercise therapy and nutritional
support to those patients in need.
Subjects Clinical Trials, Epidemiology, Kinesiology, Oncology, Otorhinolaryngology
Keywords Cancer, Chemo-radiation therapy, Deconditioning, Muscle strength,
Physical performance, SARC-F, Skeletal muscle mass, Resistance training
INTRODUCTION
Current statistics indicate that India accounts for over one sixth of the world’s population.
Head and neck cancers (HNC) are one of the most common cancers worldwide and
account for the majority (25–30%) of all cancers in India, with rates even higher in Indian
men than women (Dandekar et al., 2017). Poor oral hygiene, smoking, smokeless tobacco
products, alcohol use and human papilloma virus infections are believed to be some of the
major contributors to the high incidence rates for HNC in India (Jemal et al., 2011).
In Indian patients with HNC, the severity of the cancer is typically described using a
four stage approach. A single modality treatment (either surgery or radiotherapy) is used
in stage I and II (early stage), while multimodality treatment (surgery with radiotherapy
(RT) and/or chemotherapy, chemo-radiotherapy (CRT)) is more commonly used in
advanced stages (III and IV) (Dandekar et al., 2017). While loco-regional control and good
disease speciﬁc survival rates are being achieved by CRT, these treatments are associated
with unique short-term and long-term adverse events (Pulte & Brenner, 2010). A number
of HNC patient groups receiving CRT may also experience substantial declines in muscle
mass, muscle strength and physical performance (Ganju et al., 2019; Harada et al., 2016;
Ida et al., 2015; Sato et al., 2018), all of which are components of the diagnosis of the geriatric
condition, sarcopenia. Of further concern, HNC patients undergoing CRT who develop
sarcopenia experience approximately twice the rate of CRT toxicity, six times the rate of
respiratory complications and a halving of the progression-free and overall survival rates
compared to their peers without sarcopenia (Ganju et al., 2019;Harada et al., 2016; Ida et al.,
2015; Sato et al., 2018).
While a number of deﬁnitions and diagnostic criteria have been developed for
sarcopenia, the European Working Group on Sarcopenia in Older People (EWGSOP)
appears to be the most commonly used (Cruz-Jentoft et al., 2010, 2014). Recently, a revised
EWGSOP deﬁnition and diagnostic criteria (referred to as EWGSOP2) has been developed
based on the research conducted since the initial consensus (Cruz-Jentoft et al., 2019).
The EWGSOP2 still focuses on the same three sarcopenic outcomes (muscle mass, muscle
strength and physical performance), but now identiﬁes muscle strength as a key
determinant of sarcopenia and recommends it be assessed ﬁrst. The EWGSOP2
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acknowledges that the assessment of muscle mass by dual energy X-ray absorptiometry,
magnetic resonance imaging or bioelectrical impedance ca be expensive and
time-consuming for routine clinical use and as a result now recommends the SARC-F as a
screening tool for sarcopenia (Cruz-Jentoft et al., 2019), especially in clinical practice.
Internationally, the prevalence of sarcopenia in HNC patients has been demonstrated to
be high, although there is considerable between-study variation (16–71%) (Elliott et al.,
2017; Ganju et al., 2019;Harada et al., 2016; Ida et al., 2015; Sato et al., 2018). Regardless of
these between-study variations, the prevalence of sarcopenia in HNC patient groups
appear substantially greater than that observed for community dwelling older adults, for
which a prevalence of 1–29% has been reported in 15 studies across nine countries
(Cruz-Jentoft et al., 2014).
Of additional concern to Indian HNC cancer patients, Indians have a reduced body
mass index, higher percentage body fat and reduced skeletal muscle mass and strength
than many other ethnic groups including Caucasians (Kapoor et al., 2019; Kryst et al., 2019;
Marwaha et al., 2014). Speciﬁcally, an international study involving 18,363 older adults
(aged 65 years and older) from three European, three Asian, two African and one South
American country, demonstrated higher sarcopenia prevalence rates in older Indians
(17.5%) than the other eight countries assessed (12.6–16.7%) (Tyrovolas et al., 2016).
A similar study involving 10,892 adults aged 65 years and older from three Asian, two
African and one North American country demonstrated that India had the second worst
handgrip strength scores, with 50% of older Indian men having below normal grip strength
(Brennan-Olsen et al., 2019).
It is therefore possible that as a function of India’s greater sarcopenia prevalence rates
and the relative lack of allied health services in Indian hospitals, that Indian HNC patients
may be at even greater risk of developing sarcopenia and sarcopenia-related adverse events
than those in other more developed countries. Such issues suggest that sarcopenia
screening programs may need to considered for at-risk Indian populations such as
advanced HNC patients, especially those considering undergoing CRT. One potentially
feasible approach may be the routine use of the EWGSOP2-recommended SARC-F
(Cruz-Jentoft et al., 2019).
The SARC-F is a self-report tool consisting of ﬁve questions (items) that takes ~2 min to
complete, with the items focusing on the older individual’s perception of their muscular
strength, ability to walk, rise from a chair and climb stairs as well as fall status (Malmstrom
& Morley, 2013). Of particular relevance to the study involving Indian HNC patients,
the SARC-F has been demonstrated to exhibit reasonable validity and/or reliability
when used by older adults across a variety of countries and languages (Bahat et al., 2018;
Cao et al., 2014; Ida et al., 2017; Malmstrom et al., 2016; Rodriguez-Rejon et al., 2018).
Due to the size of the Indian population, its high HNC cancer and sarcopenia
prevalence and its developing healthcare system, we feel that substantially greater research
needs to be conducted on Indian cancer patients to see if the considerable international
research can be directly applied to the Indian context. Such research is crucial, as a
relatively recent systematic review identiﬁed only 13 studies that examined the beneﬁts of
exercise for Indian cancer patients (Samuel et al., 2015).
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Therefore, the two speciﬁc aims of this pilot study were to: (1) quantify
sarcopenic-related outcomes in an at-risk population (HNC patients about to undergo
CRT); and (2) to gain some insight into how these outcomes may change over 7 weeks of
CRT. It was hypothesized that these patients would have relatively normal sarcopenic
outcomes when commencing CRT, but that 7 weeks of CRT would result in a substantially
greater incidence of probable sarcopenia as identiﬁed by the SARC-F and signiﬁcant
declines in muscle mass, muscle strength and physical performance would be observed
during CRT.
MATERIALS AND METHODS
Participants
This short-term, longitudinal cohort study sought to quantify the potential change in
probable sarcopenia diagnosis (as assessed by the total SARC-F score), muscle mass,
strength and physical performance in HNC patients receiving CRT using assessments that
are endorsed by EWGSOP2 as valid and feasible for use in clinical practice (Cruz-Jentoft
et al., 2019). To be eligible to participate in this study, participants had to at least 30 years
old, with a head or neck carcinoma (Stage III, IVa or IVb) and admitted to an oncology
department for a 7 weeks course of CRT (radiation of 70 Gy and Cisplatin dose of
chemotherapy 40 mg/m2), administered on a weekly basis. Participants with orthopedic
and neurological problems or an inability to comply with the study procedure were
ineligible. Participants who were included in the study were all admitted to the university
hospital from December 2018 to February 2019 and screened for inclusion and exclusion
after signing the informed consent form. Ethical approval was obtained from the
Institutional Research Committee and Ethical Committee from Kasturba Medical College,
Mangalore.
Procedures
In order to ensure consistency of testing time and hydration status, all assessments were
conducted on the patients within 1–2 h of ﬁnishing their lunch. Participants completed
the SARC-F self-report sarcopenia screening tool which consists of ﬁve questions, each
scored from 0 to 2 (Malmstrom & Morley, 2013). The ﬁrst four questions assessed walking
speed, walking assistance, chair rise and stair climbing ability, with each question graded
as: no (0), some (1) or an inability (2) to perform a given task, respectively. The last
question assessed falls history in the previous year and was graded as: no falls (0), 1–3 falls
(1) and 4 or more falls (2). Total SARC-F scores ≥4 are indicative of probable sarcopenia
(Malmstrom et al., 2016).
Skeletal muscle mass was assessed by the OMRON Karada Scan Hbf 375 Body
Composition Monitor (Gibson, Heyward & Mermier, 2000). Participants were asked to
step onto the measurement platform, by placing the feet on the foot electrodes and to grip
the hand electrodes and extend their arms straight at a 90 angle to the body. Muscle
strength was assessed by Jamar handgrip dynamometer, with the participants seated,
adduction in their shoulder joint, elbow ﬂexed at 90 and forearm in the neutral position.
The participant was asked to squeeze the hand dynamometer with their preferred hand as
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hard as possible for 4–5 s, during 3 trials, each trial separated by one minute (Figueiredo
et al., 2007). Physical performance was assessed by the Timed-Up and Go test, wherein the
participants were asked to stand up from a stable chair with armrest, walk to and turn
around a cone positioned 3 m in front of the chair and regain a seated position as quickly
as possible. In this test, participants were allowed to use the armrest if needed during the
sit-stand phase. The largest handgrip score and the fastest Timed-Up and Go trial were
recorded for data analysis (Shumway-Cook, Brauer & Woollacott, 2000).
Statistical analysis
A comparison of means of the outcome variables to their standard deviations, indicated
that the means were almost always substantially greater and twice the standard deviation,
which implies that data was normally distributed (Peat & Barton, 2005). Therefore,
descriptive statistics including means and standard deviations were used to describe the
participants demographic characteristics and sarcopenic outcomes over the three
timepoints (baseline, third week and seventh week of CRT). Repeated measure analysis of
variance was performed to identify if any signiﬁcant differences occurred for any of the
dependent variables over the three time points. Wherever signiﬁcant differences were
observed, post–hoc Bonferroni tests were used to identify which timepoints were
signiﬁcantly different. For all statistical tests, a p-value ≤ 0.05 was considered to indicate
statistical signiﬁcance.
RESULTS
The demographics of the 19 participants at recruitment was 56.5 ± 10.2 years, with the
majority (n = 13, 68.4%) engaged in laboring occupations (see Table 1). At baseline, 31.5%
(n = 6) of the participants already had probable sarcopenia based on their total SARC-F
score, with this increasing to 89.4% (n = 17) at the conclusion of seven weeks of CRT
(see Table 2). A signiﬁcant decline in all of the sarcopenic outcomes was observed after
three weeks of CRT, with this even more pronounced after seven weeks of CRT.
DISCUSSION
The major ﬁndings of this pilot study were that sarcopenia and its associated adverse
events may be highly prevalent in advanced stage (Stage III, IVa or IVb) Indian HNC
patients, especially after completing seven weeks of CRT. The tendency for poor
sarcopenic outcomes to be observed even prior to starting CRT was quite concerning due
to the relatively young (mean age of 56.5 years, range 39–75 years) of the HNC patients in
the study. Speciﬁcally, prior to starting CRT, close to one third (31.5%) of the participants
had probable sarcopenia based on their total SARC-F score ≥ 4 (Malmstrom & Morley,
2013). The sarcopenia prevalence of 31.5% prior to starting CRT was considerably greater
than that observed in three studies of community dwelling Indians with mean ages of
70–74 years (8–17%) (Anand et al., 2019; Mohanty & Sahoo, 2016; Tyrovolas et al., 2016).
It was also some concern that prior to undergoing CRT, that the mean handgrip strength
(26.1 kg) of our participants was fractionally under the below normal (sarcopenic)
threshold of 27 kg for men (Cruz-Jentoft et al., 2019). This low level of handgrip strength
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was consistent with a large international study of 10,892 older participants, in which 50%
of Indian men over 65 years of age had below normal handgrip strength (Brennan-Olsen
et al., 2019). Collectively, these results indicate that the advanced Indian HNC patients
with a mean age of 55 years who were involved in the present study, had a greater
Table 1 Baseline characteristics of the head and neck cancer participants.
Outcome Value
Age (year) 56.5 ± 0.2
Height (cm) 162.4 ± 7.4
Body mass (kg) 47.2 ± 10.3
Body mass index (kg·m−2) 17.8 ± 2.9
Occupation
Labourer 13 (68.4%)
Agriculturalist 3 (15.8%)
Mechanic 1 (5.3%)
Priest 1 (5.3%)
Tailor 1 (5.3%)
Cancer stage
Stage III 12 (63.2%)
Stage IV 7 (36.8%)
Cancer location
Tongue 5 (26.3%)
Hypophyarynx 3 (15.8%)
Buccal mucossa 2 (10.5%)
Oral cavity 2 (10.5%)
Oropharynx 2 (10.5%)
Supraglottis 2 (10.5%)
Tonsil 2 (10.5%)
Tonsillar fossa 1 (5.3%)
Note:
All data are presented as means ± standard deviation, with the exception of cancer stage and cancer location, whereby the
data is presented as number (percentage).
Table 2 Changes in sarcopenic-related outcomes in head and neck cancer participants.
Tools Baseline 3rd week 7th week
SARC-F 2.6 ± 1.6 3.6 ± 1.5a 4.7 ± 1.4a,b
Individuals with probable sarcopenia
(i.e. Total SARC-F score ≥ 4.0)
6 (31.5%) 10 (52.6%) 17 (89.4%)
Handgrip strength (kg) 26.1 ± 6.0 23.3 ± 6.2a 20.4 ± 5.6a,b
Skeletal muscle mass (kg) 29.9 ± 3.0 28.7 ± 3.3a 26.4 ± 3.8a,b
Timed Up and Go (s) 10.1 ± 2.7 10.9 ± 2.9a 12.1 ± 3.0a,b
Notes:
All data are presented as means ± standard deviation, with the exception of individuals with probable sarcopenia,
whereby the data is presented as number (percentage) of participants with probable sarcopenia.
a Signiﬁcantly different (p < 0.05) than baseline.
b Signiﬁcantly different (p < 0.05) than third week.
Chauhan et al. (2020), PeerJ, DOI 10.7717/peerj.8617 6/12
prevalence of sarcopenia and comparably poor levels of handgrip strength to that observed
in larger studies of Indian older adults aged 65 years and above.
Of even greater concern than the baseline scores, was the signiﬁcant increase in
probable sarcopenia and declines in muscle strength, muscle mass and physical
performance across the seven weeks of CRT. For example, the number of HNC patients
with probable sarcopenia based on a total SARC-F score ≥4, increased from 31.5% at
baseline to 52.6% and 89.4%, after three weeks and seven weeks, respectively of CRT.
The rates of sarcopenia for our relatively young participants at seven weeks CRT (89.4%)
were approximately ﬁve times higher than normative data for India adults over the age
of 65 years of 17% (Tyrovolas et al., 2016) and over twice as high as that observed in older
Indians (mean age of 70 years) with vertebral fractures (38%) (Anandi et al., 2016).
These sarcopenia results also appear substantially greater than the international studies of
HNC patients that have indicated sarcopenia prevalence rates of 16–71% (Elliott et al.,
2017; Ganju et al., 2019; Harada et al., 2016; Ida et al., 2015; Sato et al., 2018).
The HNC patients also experienced signiﬁcant declines of ~5.7 kg (22%) in handgrip
strength, 3.3 kg (11%) in muscle mass and 2.0 s (20%) in Timed-Up and Go test
performance after seven weeks of CRT. Such declines appear of clinical signiﬁcance as
they exceed the minimal clinically important difference (MCID) of 5 kg for handgrip
strength (Lang et al., 2008) and ~1.3 s for the Timed-Up and Go test (Alghadir, Anwer &
Brismée, 2015; Wright et al., 2011). Collectively, the increased total SARC-F scores and
declines in handgrip strength, muscle mass and Timed-Up and Go test performance
are reﬂective of increased impairment and disability in this patient group that have the
potential to reduce the patients’ general well-being and overall quality of life. Beyond
these functional consequences of these losses in muscle strength, muscle mass and
physical performance, such declines have also been associated with signiﬁcantly greater
risk of CRT toxicity, respiratory complications and declines in progression-free and
overall survival in HNC patients (Ganju et al., 2019; Harada et al., 2016; Ida et al., 2015;
Sato et al., 2018).
As a result of these clinically signiﬁcant declines in muscle strength, muscle mass and
physical performance observed during seven weeks of CRT and the association between
sarcopenia and a host of adverse events in HNC patients, oncologists and their allied
health care teams, especially those in India, may need to consider a number of alterations
to the usual care strategies for these patients. The ﬁrst may be the implementation of
routine monitoring of some of the sarcopenic-related outcomes used in the present study
to help identify patients who are at risk of sarcopenia and the associated adverse events
(Baxi, Schwitzer & Jones, 2016; Ganju et al., 2019). Such monitoring may be useful to
implement on at least an annual basis with advanced HNC patients, especially those
considering CRT, as sarcopenia can reduce CRT compliance, and increase their risk of
adverse events and early mortality. Based on simplicity and clinical relevance of the
recommendations of the EWGSOP2, we would recommend that the oncology healthcare
teams should routinely assess SARC-F and/or handgrip strength test (Cruz-Jentoft et al.,
2019), with such assessments only taking a handful of minutes to complete. It is even
possible that the SARC-F monitoring could be performed by the patient themselves, as a
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recent study demonstrated that changes in older adults’ SARC-F scores match that of
quantitative assessments of muscle strength and physical performance performed by their
allied health professionals (Keogh et al., 2019).
For those HNC patients who are diagnosed with sarcopenia and appear at risk of
developing sarcopenic adverse events, clinicians should look to ensure their patients have
exercise rehabilitation and/or nutritional support. Speciﬁcally, clinicians should look to
follow the recommendations of a Society of Sarcopenia, Cachexia and Wasting Disorders
position statement, by ensuring these patients complete 2–3 sessions per week of
progressive resistance training and obtain protein intakes of up to 1.5 g/kg bodyweight per
day to offset these sarcopenic-related treatment effects (Bauer et al., 2019). Consistent with
these guidelines, exercise programs involving substantial components of progressive
resistance training have been demonstrated to be safe and feasible, and able to signiﬁcantly
increase muscle strength, physical performance and quality of life and approach statistical
signiﬁcance for reduced fatigue in international (Grote et al., 2018) and Indian (Samuel
et al., 2019, 2013) studies of HNC patients. Such results further support the importance of
physiotherapists providing exercise therapy to Indian HNC patients undergoing CRT,
with dietitians also having an important role to ensure these patients obtain sufﬁcient
protein (Bauer et al., 2019).
CONCLUSIONS
The results of this pilot study demonstrated that even prior to receiving CRT, Indian Stage
III, IVa or IVb HNC patients may be at elevated risk of sarcopenia (compared to their
age-matched peers) and in developing sarcopenic-related adverse events, with this
becoming much more pronounced at the completion of seven weeks of CRT. As this is
only a pilot study involving a small number of male patients, it would be recommended
that future studies are conducted in order to conﬁrm the exploratory results presented in
this manuscript. If similar ﬁndings are observed in future studies, it is recommended that
oncologists work closely with physiotherapists and dieticians to routinely monitor these
patient groups for sarcopenia and intervene with evidence-based exercise and nutritional
support where required.
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